The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis

Journal of Trace Elements in Medicine and Biology

Volumn 28, Issue 2, 2014, Pages 194-199

  Dias, Paula Cristina Silveira ^a   Sena Evangelista, Karine Cavalcanti Mauricio ^a   Paiva, Maria Sanali Moura de Oliveira ^a   Ferreira, Diana Quitéria Cabral ^a   Ururahy, Marcela Abbott Galvão ^a   Rezende, Adriana Augusto ^a   Abdalla, Dulcinéia Saes Parra ^b   Pedrosa, Lucia Fatima Campos ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Metallothionein; Rosuvastatin; Zinc supplementation

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; ZINC; BIOLOGICAL MARKER; FLUOROBENZENE; METALLOTHIONEIN; MT1F PROTEIN, HUMAN; MT2A PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; GENE; GENE EXPRESSION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MT1F GENE; MT2A GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; ZINC BLOOD LEVEL; ANTHROPOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS;

ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIETARY SUPPLEMENTS; FEMALE; FLUOROBENZENES; GENE EXPRESSION REGULATION; HUMANS; MALE; METALLOTHIONEIN; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLACEBOS; PYRIMIDINES; SULFONAMIDES; ZINC;

EID: 84898052139     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.01.003     Document Type: Article

References (36)

1. Little P., Bhattacharya R., Moreyra A., Korichneva I. Zinc and cardiovascular disease. Nutrition 2010, 26:1050-1057.
2. Hennig B., Meerarani P., Ramadass P., Toborek M., Malecki A., et al. Zinc nutrition and apoptosis of vascular endothelial cells: implications in atherosclerosis. Nutrition 1999, 15:744-748.
3. Beattie J., Kwun I. Is zinc deficiency a risk factor for atherosclerosis. Br J Nutr 2004, 91:177-181.
4. Hambidge K., Miller L., Westcott J., Sheng X., Krebs N. Zinc bioavailability and homeostasis. Am J Clin Nutr 2010, 91:1478-1483.
5. Blindauer C., Leszczyszyn O. Metallothioneins: unparalleled diversity in structures and functions for metal ion homeostasis and more. Nat Prod Rep 2010, 27:720-741.
6. Andrews G. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 2000, 59:95-104.
7. Mocchegiani E., Costarelli L., Giacconi R., Cipriano C., Muti E., et al. Zinc-binding proteins (metallothionein and a-2 macroglobulin) and immunosenescence. Exp Gerontol 2006, 4:1094-1107.
8. Alissa E., Bahjri S., Ahmed W., Al-Ama N., Ferns G. Trace element status in Saudi patients with established atherosclerosis. J Trace Elem Med Biol 2006, 20:105-114.
9. Yang Y., Choi B., Chun B., Kweon S., Lee Y., et al. Dietary zinc intake is inversely related to subclinical atherosclerosis measured by carotid intima-media thickness. Br J Nutr 2010, 104:1202-1211.
10. Murr C., Pilz S., Grammer T., Kleber M., Böhm B., et al. Low serum zinc levels in patients undergoing coronary angiography correlate with immune activation and inflammation. J Trace Elem Med Biol 2012, 26:26-30.
11. Ghayour-Morbarhan M., Lamb D., Taylor A., Vaidya N., Livingstone C., et al. Effect of statin therapy on serum trace element status in dyslipidemic subjects. J Trace Elem Med Biol 2005, 19:61-67.
12. Yilmaz M., Baykal Y., Sonmez A., Bulucu F., Aydin A., et al. Effects of statins on oxidative stress. Biol Trace Elem Res 2004, 98:119-127.
13. Lim S.Y. Role of statins in coronary artery disease. Chonnam Med J 2013, 49:1-6.
14. Costarelli L., Muti E., Malavolta M., Giacconi R., Cipriano C., et al. Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors. Rejuvenation Res 2008, 11:287-291.
15. Mocchegiani E., Malavolta M., Muti E., Costarelli L., Cipriano C., et al. Zinc, metallothioneins and longevity: interrelationships with niacin and selenium. Curr Pharm Des 2008, 14:2719-2732.
16. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol in adults. JAMA 2001, 285:2486-2497.
17. Sena K., Arrais R., Almeida M., Araújo D., Santos M., et al. Effects of zinc supplementation in patients with type 1 diabetes. Biol Trace Elem Res 2005, 105:1-9.
18. Livak K., Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) method. Methods 2001, 25:402-408.
19. Gómez-García A., Martínez-Torres G., Ortega-Pierres L., Rodríguez-Ayala E., Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007, 60:1242-1249.
20. Miname M., Santos R. Use of C-reactive protein to prevent atherosclerosis: between Jupiter and Mars. Rev Assoc Med Bras 2009, 55:502-504.
21. Ridker P., Danielson E., Fonseca F., Genest J., Gotto A., et al. JUPITER trial study group. reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 4:1175-1782.
22. Bots M., Raichlen J., Evans G., Palmer M., O'Leary D., et al. Rosuvastatin reduces progression of carotid atherosclerosis within 12 months of treatment: the METEOR trial. Circulation 2007, 116:698-707.
23. Rosenson R. Statins in atherosclerosis: lipid-lowering agents with antioxidants capabilities. Atherosclerosis 2004, 173:1-12.
24. Farrokhi F., Moohebati M., Aghdaei H., Ghaffarzadegan K., Norouzi F., et al. Effects of statin therapy on serum trace element status in dyslipidemic patients: results of a randomized placebo-controlled cross-over trial. Clin Lab 2012, 58:1005-1015.
25. Andersen H., Nielsen J., Nielsen F., Grandjean P. Antioxidative enzyme activities in human erythrocytes. Clin Chem 1997, 43:562-568.
26. Mocchegiani E. MT mRNA gene expression via IL-6 and glucocorticoids, as potential genetic marker of immunosenescence: lessons from very old mice and humans. Exp Gerontol 2002, 37:349-357.
27. Varshney U., Jahroudi N., Foster R., Gedamu L. Structure, organization, and regulation of human metallothionein IF gene: differential and cell-type-specific expression in response to heavy metals and glucocorticoids. Mol Cell Biol 1986, 6:26-37.
28. Richards R., Heguy A., Structural Karin M. functional analysis of the human metallothionein-IA gene: differential induction by metal ions and glucocorticoids. Cell 1984, 37:263-272.
29. Overbeck S., Rink L., Haase H. Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases. Arch Immunol Ther Exp 2008, 56:15-30.
30. Cragg R., Phillips S., Piper J., Varma J., Campbell F., et al. Homeostatic regulation of zinc transporters in the human small intestine by dietary zinc supplementation. Gut 2005, 54:469-478.
31. Neve J., Hanocq M., Peretz A., Abi Khalil F., Pelen F. Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms. J Pharm Belg 1993, 48:5-11.
32. Mariani E., Mangialasche F., Feliziani F., Cecchetti R., Malavolta M., et al. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Exp Gerontol 2008, 43:445-451.
33. Giacconi R., Muti E., Malavolta M., Cipriano C., Costarelli L., et al. The +838C/G MT2A polymorphism, metals, and the inflammatory/immune response in carotid artery stenosis in elderly people. Mol Med 2007, 13:388-395.
34. Mocchegiani E., Giacconi R., Costarelli L., Muti E., Cipriano C., et al. Zinc deficiency and IL-6 -174G/C polymorphism in old people from different European countries: effect of zinc supplementation. ZINCAGE study. Exp Gerontol 2008, 43:433-444.
35. Sulivan V., Burnett F., Cousins R. Metallothionein expression is increased in monocytes and erythrocytes of young men during zinc supplementation. J Nutr 1998, 128:707-713.
36. Aydemir T., Blanchard R., Cousins R. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. Proc Natl Acad Sci USA 2006, 103:1699-1704.